Healthcare systems need to deliver more care while controlling rising costs — even as they grapple with funding models that contribute to inefficiencies, unnecessary medical procedures, and inconsistent quality levels. As this Viewpoint explores, value-based contracting (VBC) is transforming healthcare by linking payment for treatments, technologies, and services to their outcomes. This leads to insurers paying for results, providers delivering cost-effective and personalized care, and patients more easily accessing innovative therapies.
In the last 20 years, healthcare systems have focused on achieving the triple aim of improving population health and patient experience at a lower cost per capita. Unfortunately, the inherent tension between outcomes, quality, and cost makes it difficult to strike an optimal balance. Governments and insurers seek cost-containment strategies that do not compromise care quality, while patients expect better health outcomes/personalized treatments and healthcare providers seek full reimbursement for delivering effective and safe treatments.
Value-based healthcare resolves these conflicting objectives by aligning rewards with outcomes and care quality at a population level rather than a transactional one. In VBC, this concept is applied to the financial arrangements between payers, providers, and suppliers to ensure treatments, technologies, and services are paid for when they deliver their expected benefits.
This Viewpoint examines the principles of VBC, its potential benefits, and the challenges associated with its adoption. We present a framework to guide its implementation and highlight early successes through case studies from mature markets such as the US, the UK, and the Netherlands and how they can be applied in emerging markets such as the Kingdom of Saudi Arabia (KSA). By transitioning to a value-driven approach, healthcare systems have been able to improve patient care, optimize resource consumption, and align the competing priorities of payers, regulators, and drug/device manufacturers.
Global healthcare systems are under pressure from rising demand due to aging populations, chronic disease prevalence, and increased use of services. Innovations like gene therapies and advanced diagnostics offer major benefits but strain limited resources. Healthcare expenditure continues to escalate, driven by medical inflation, expensive new treatments, and workforce shortages, as evidenced in many markets (see Figure 1).
High-cost innovations like cell and gene therapies raise tough questions about affordability and access. For example, when the drug sacituzumab govitecan (a treatment for metastatic triple-negative breast cancer) was initially not approved by UK regulator NICE (National Institute for Health and Care Excellence) because of cost concerns, thousands of patients were impacted. Healthcare systems that can tie reimbursement to treatment effectiveness are better able to introduce innovative therapies.
Care quality also varies widely, with inconsistent outcomes across regions and providers, leading to preventable complications and higher costs. Fee-for-service (FFS) models continue to dominate because they’re easier to manage and incent productivity, but they reward volume over value, which fuels inefficiencies and cost escalation.
There is a growing recognition that a fundamental shift must occur to encourage cost-effective interventions while ensuring that quality and patient outcomes remain a priority. With a value-based approach, healthcare systems gain the ability to balance cost containment with the imperative to deliver high-quality, innovative care on a sustainable basis.
In healthcare, value is the degree to which healthcare services contribute to positive health outcomes for patients at the lowest cost while ensuring a positive patient experience and promoting population health. In value-based healthcare, the emphasis is on improving long-term health outcomes rather than episodic interventions. This is measured by metrics such as hospital readmission rates, mortality rates, and patient satisfaction. By aligning financial incentives with these value-driven outcomes, value-based healthcare aims to improve the quality, efficiency, and effectiveness of healthcare services.
Traditionally, reimbursement has been based on an FFS model: providers are compensated for patient visits and procedures rather than the effectiveness of the care provided. Occasionally, some form of outcome or value metric is included, but in general, FFS models lead to unnecessary treatments, fragmented care, and rising healthcare expenditure.
In value-based healthcare, a contract establishes an agreement between payers (e.g., insurance companies), healthcare providers (e.g., hospitals and clinics), and suppliers (e.g., drug and device manufacturers), in which price and payment are tied to clinical or economic results. The key differences are shown in Figure 2.
In summary, VBC:
VBC is applicable to both traditional and new treatments, technologies, and services. VBC models support the objectives of each, taking into account their specific cost and expected patient volumes. For simplicity, we examine three categories, into which any existing or new treatment, technology, or service can be classified (see Figure 3):
In high-demand/moderate-cost scenarios, FFS rewards the volume of services provided, regardless of quality or outcomes. VBC, in contrast, lets healthcare systems standardize clinical pathways, contain costs, and improve care quality. For example, with bundled payments, healthcare providers share financial risk and are thus incented to reduce complications and avoid readmissions.
By aligning incentives between payers and providers, this model promotes efficiency, lowers costs, and ensures high-quality care — shifting the focus from quantity to performance.
In medium-volume/relatively high-cost scenarios, risk-sharing mechanisms help distribute financial and clinical responsibility, ensuring cost-effective care. Additionally, long-term tracking of patient outcomes enables continuous quality improvement and the means to identify best practices that enhance efficiency and effectiveness.
In low-volume/extremely high-cost scenarios (e.g., emerging therapies), there is a significant financial burden on payers. High-cost therapies for unmet needs offer transformative potential but carry long-term uncertainty, posing risks to health systems. VBC ties reimbursement to real-world performance as a way to resolve this issue.
VBC adoption involves a fundamental shift in how healthcare agreements are structured and managed. VBC is more complex than traditional approaches, requiring risk-sharing, stakeholder collaboration, and performance tracking. Contracting frameworks must evolve to accommodate biparty and multiparty agreements, include tracking of real-world evidence, and align financial incentives with clinical/financial results and patient-reported outcomes. Healthcare systems making this transition need a structured framework like the one shown in Figure 4. Each component is described in detail below.
cloud technology axon
The deal integrates into Condis’ structure eight supermarkets locate...
